학술논문
Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
Document Type
Letter
Source
Subject
*STAT proteins
*IMMUNE response
*COVID-19 vaccines
*INTERFERON gamma
*COVID-19
*INFECTION
*
*
*
*
*
Language
ISSN
0271-9142
Abstract
Recently, two STAT1 GOF CMC patients were reported to mount a normal vaccine-specific anti-spike 1 antibody response and one who failed to do so [[15]]. Results Seven adult Czech STAT1 GOF CMC patients (previously described p.Y68C, p.A267V, p.M390T and novel p.T288N and p.E29A; cohort characteristics detailed in Supplementary Table 1) received SARS-CoV-2 spike 1 protein-encoding mRNA vaccine (Comirnanty®, Pfizer/BioNTech). Conversely, STAT1 GOF patients receiving JAK inhibitors, such as ruxolitinib, may have blunted vaccine response, due to the artificially suppressed JAK/STAT pathway. Here, we report seven adult STAT1 GOF patients (two with novel mutations) with an uneventful course of COVID-19 vaccination, and/or SARS-CoV-2 infection, including two patients receiving JAK inhibitor ruxolitinib. [Extracted from the article]